Furthermore, in the subset of patients with ERBB2-positive disease undergoing upfront surgery, information on nodal status is relevant to properly tailor adjuvant treatment, which in node-negative disease might be restricted to paclitaxel and trastuzumab.24 In addition, in patients with small triple-negative BC undergoing upfront surgery, pathological staging of nodal status might be relevant to modulate the postoperative treatment plan. The gene discussed is ERBB2; the disease is breast cancer.